百利天恒：注射用iza-bren(EGFR×HER3双抗ADC)纳入突破性治疗品种名单

Group 1 - The company, Bai Li Tian Heng (688506.SH), has announced that its self-developed drug, iza-bren (EGFR × HER3 dual antibody ADC), is the first-in-class and new concept therapy that has entered Phase III clinical trials for patients with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [1] - The drug has been included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center, and the announcement has recently been made public [1]